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The Crystal Structure of 
Pneumolysin at 2.0 Å Resolution 
Reveals the Molecular Packing of 
the Pre-pore Complex
Jamie E. Marshall1, Bayan H. A. Faraj1, Alexandre R. Gingras2,†, Rana Lonnen1, 
Md. Arif Sheikh1,‡, Mohammed El-Mezgueldi2, Peter C. E. Moody2, Peter W. Andrew1 & 
Russell Wallis1,2
Pneumolysin is a cholesterol-dependent cytolysin (CDC) and virulence factor of Streptococcus 
pneumoniae. It kills cells by forming pores assembled from oligomeric rings in cholesterol-containing 
membranes. Cryo-EM has revealed the structures of the membrane-surface bound pre-pore and 
inserted-pore oligomers, however the molecular contacts that mediate these oligomers are unknown 
because high-resolution information is not available. Here we have determined the crystal structure 
of full-length pneumolysin at 1.98 Å resolution. In the structure, crystal contacts demonstrate the 
likely interactions that enable polymerisation on the cell membrane and the molecular packing of the 
pre-pore complex. The hemolytic activity is abrogated in mutants that disrupt these intermolecular 
contacts, highlighting their importance during pore formation. An additional crystal structure of the 
membrane-binding domain alone suggests that changes in the conformation of a tryptophan rich-
loop at the base of the toxin promote monomer-monomer interactions upon membrane binding by 
creating new contacts. Notably, residues at the interface are conserved in other members of the CDC 
family, suggesting a common mechanism for pore and pre-pore assembly.
The cholesterol-dependent cytolysin (CDC), pneumolysin1 is a virulence factor of the human pathogen 
Streptococcus pneumoniae (pneumococcus)2, the leading cause of bacterial pneumonia and a major agent 
of meningitis and septicaemia as well as debilitating diseases such as otitis media, septic arthritis, keratitis 
and sinusitis3. It is found in virtually all pneumococcal isolates and plays key roles in bacterial colonisa-
tion, invasion and inflammation4–6. A central feature of the toxin is the formation of transmembrane pores 
in cholesterol-containing membranes7, which lyse or disrupt cell functioning, depending on the concen-
tration8–10. Pneumolysin and other CDCs bind to mammalian membranes through a tryptophan-rich 
loop and a threonine-leucine pair within a membrane-binding domain at the base of the toxin11,12. The 
tryptophan-rich loop has been proposed to spring out of the body of the toxin on association with the 
membrane12. All three tryptophans are implicated in membrane binding but Trp433 and Trp435 are par-
ticularly important13,14. Once bound to the membrane, monomers then oligomerise to form a pre-pore 
complex that subsequently undergoes a complex set of structural transitions to form a transmembrane 
pore, typically comprising 30–50 subunits. Structures of the pre-pore and inserted-pore oligomers have 
been determined by cryo-EM at ~28 Å, and these structures together with recent analysis of the related 
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CDC, suilysin, show that that pore formation follows the vertical collapse of the pre-pore structure with 
two extended beta-hairpins penetrating the membrane to form the large beta-barrel pore7,15.
Although high-resolution X-ray structures have been determined for several CDCs, pneumolysin 
has proved to be elusive. Consequently, structure-function analysis has relied on models based on the 
structures of the other CDC toxins. Critically, the lack of high-resolution data means that the interac-
tions enabling pneumolysin monomers to pack together to form the pore and pre-pore complexes is 
not known. In this work, we have determined the structure of pneumolysin at 1.98 Å resolution. The 
side-by-side packing arrangement in the crystal demonstrates the packing of monomers in the pre-pore 
complex. Additional structural and mutagenesis data has identified residues that are likely to contribute 
towards oligomerisation during pre-pore formation.
Results
The structure of pneumolysin. Full-length pneumolysin and a truncated form comprising the 
membrane-binding domain (domain 4) were produced by expression in E. coli and purified by affin-
ity and gel filtration chromatography. Crystals of the full-length toxin were grown at 4 °C and at pH 
8.5. The best crystals were obtained from protein containing substitutions Asp385Asn and Cys432Ala. 
Neither mutation prevents pore formation16,17. The asymmetric unit contained a single molecule having 
the characteristic four domain structure of a CDC, with three non-contiguous domains (domains 1–3) 
linked to the C-terminal membrane-binding domain (Fig.  1A) via the strap-like domain 2. Crystal of 
the membrane-binding domain were grown at room temperature and contained two molecules in the 
asymmetric unit. Both refined models have good stereochemistry (Table 1) with 95% and 93% of residues 
within the Ramachandran favoured regions.
The tryptophan-rich loop, projects from the base of domain 4 in the structure of full-length pneu-
molysin, reflecting the likely membrane-binding conformation (Fig. 1B). Notably, two of the tryptophan 
residues, Trp433 and Trp435, shown previously to be important for membrane binding and cell lysis13, 
project outwards, so are in position to allow interactions with a lipid bilayer. By contrast, the loop is 
partially folded back in the structure of domain 4 alone (Fig. 1B), and fully bent back against the body 
of domain 4 in the previously determined structure of perfringolysin O12. Together the structures are 
consistent with previous suggestion that the loop springs outwards and downwards when the toxin binds 
to the membrane of a mammalian cell (Fig. 1B)12.
Figure 1. Domain structure of pneumolysin and the likely changes upon membrane binding.  
(A) Domains 1, 2 and 3 are contiguous and connected to the C-terminal membrane-binding domain 
(domain 4) via domain 2. (B) overlay of the membrane-binding domains of the full-length pneumolysin 
(PLY), pneumolysin domain 4 (PLY D4) and perfringolysin O (PFO; PDB: 1PFO12;) structures. The 
structures reveal the likely changes that occur upon membrane binding. Notably, the tryptophan-rich loop 
flips outwards and downwards (arrow) exposing Trp433, to enable binding to the membrane.
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In the structure of full-length pneumolysin, domain 4 is offset by ~30° relative to the plane of the 
long axis of domains 1–3, such that the toxin resembles a bend rod from the side (Fig.  2A). The rel-
ative position of domain 4 differs in the available structures of CDCs. For example, it is displaced by 
∼ 15 Å and twisted by ~25° in the crystal structure of perfrigolysin O (PDB: 1PFO12;), whereas it is offset 
even further (by ~40°) in intermedilysin (18; Fig. 2A). These differences suggest flexibility at the domain 
2-domain 4 junction that would allow the toxin to dock onto the membrane surface and pack to form 
the pre-pore complex.
The monomer/monomer interface. A striking feature of pneumolysin crystals, is that monomers 
pack side-by-side in the crystal lattice, resembling the molecular packing of the pre-pore complex. 
Superimposition of two pneumolysin molecules from the crystal structure with adjacent monomers from 
the cryo-EM structure (PDB: 2BK27) gives a RMS deviation of 4.90 Å (over 849 Cα atoms; Fig.  2B). 
Most notably, domain 4 is in the correct position for membrane binding relative to the rest of the toxin 
(Fig. 2B). The interface between pneumolysin molecules is created by the concave face of one monomer 
packing against the convex face of its neighbour. Although it encompasses almost the entire long axis of 
the toxin, only a relatively small subset of residues interact (Fig. 3A). Notably these could not be predicted 
from the cryoEM structures because the resolution is too low to see the side chains. Intermolecular con-
tacts are made by all four domains, but mostly involve domains 1 and 4. There is some charge comple-
mentarity between the convex and concave faces, with the former being more negatively charged and the 
latter more positive (Fig. 3A). The interface includes 44 residues from the concave face and 41 residues 
in the convex face, with a total buried surface area of 939.6 Å2 and 962.8 Å2, respectively. Although most 
of the residues at the interface are polar, there are relatively few polar intermolecular interactions: salt 
bridges between Asp8 and Arg226 and Glu434 and Arg399 and hydrogen bonds between the side-chain 
of Asn339 and the carbonyl group of Pro87, and between the hydroxyl group of Tyr461 and the amine 
and carbonyl groups of His407. Thus, the major contribution towards oligomerization of monomers on 
the membrane is likely to be surface complementarity, leading to exclusion of water. Notably, of the 85 
Pneumolysin
Pneumolysin 
domain 4
Data collection
PDB ID Will be included in final version
Will be included in 
final version
Beam Line Diamond I04-1 Diamond I03
Space group P 21 21 21 I121
a,b,c, Å 27.1, 128.1, 172.1 48.7, 47.7, 97.5
α , β ,γ , ° 90, 90, 90 90, 101.4, 90
Resolution, Å 43.07 – 1.94  (1.99 – 1.94)
46.53 – 2.05  
(2.12 – 2.05)
Rsym 0.044 (0.461) 0.091 (0.451)
I/σ(I) 39.7 (5.84) 6.8 (2.0)
Completeness 99.4 (99.9) 99.4 (97.8)
Redundancy 6.2 (6.3) 2.9 (2.4)
Refinement
Resolution 43.07 – 1.98  (2.05 – 1.98)
46.53 – 2.05  
(2.12 – 2.05)
No. reflections 42799 (4227) 40468 (2447)
Rwork/Rfree 0.246/0.269 0.218/0.271
No of atoms 3856 2021
Protein 3661 1870
water 195 151
B-factors, Å2 67.2 35.0
Protein 68.1 35.1
water 51.4 33.6
Rms deviations
Bond lengths, Å 0.004 0.004
Bond angles, ° 0.81 0.83
Table 1.  Data collection and refinement statistics. The highest resolution shell is shown in parentheses.
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residues that are buried, 41 are identical and 63 are conserved in at least three of the other CDCs for 
which structures are available, suggesting that the interface is likely to be relatively well conserved in 
other CDCs (Fig.  3B). This conclusion is supported by comparison of the pneumolysin structure with 
the crystal structures of intermedilysin19 and listeriolysin O20, which also pack side-by-side in the crystal. 
Remarkably, contacts in the three structures involve equivalent regions of the CDC polypeptides, and 
many of the interacting residues are conserved (Fig. 3B).
Mutation of residues at the monomer/monomer interface leads to loss of cytolytic activ-
ity. To test whether the intermolecular contacts observed in the crystal are important for the activity of 
the toxin, mutations were introduced to residues and the resulting cytolytic activity was measured using a 
simple haemolytic assay. In total, 18 single mutations were made to surface-exposed residues. Mutations 
Arg399Ala and Glu434Ala were designed to disrupt the salt bridge between adjacent membrane-binding 
domains and Tyr461Phe and Tyr461Ala to prevent the hydrogen bond between Tyr461 and the main 
chain of His407. Additional, mutations were introduced to disrupt the hydrophobic packing by remov-
ing side chains that pack against the adjacent monomer or by introducing large charged groups (Glu 
or Arg) at the interface. Leu11Arg, Ser68Glu, Asn86Arg, Thr88Glu, Arg147Ala, Asp205Arg Arg226Ala 
Thr304Arg, Asp338Ala, Ser68Glu, Asn86Arg, Arg147Glu, Asp338Arg were designed to disrupt the inter-
face at the top of toxin (domains 1–3) and Arg437Ala to disrupt the domain 4/domain 4 interface. 
Although mostly polar in nature, these residues do not form intermolecular polar contacts, but rather 
exclude water at the interface Three double mutants were also created with mutations in domain 4: 
Arg339Ala + Glu434Ala; Glu434Ala + Tyr461Ala; and Glu434Ala + Arg437Ala. Importantly, with the 
exception of Arg147, which lies on the domains 1/3 boundary and Thr304 within domain 3, mutagenesis 
was restricted to residues in domains 1 and 4 that undergo relatively little positional changes upon pore 
formation. Regions undergoing large conformational changes, including residues 155–186 and 253–285 
that form the membrane-spanning β -hairpins and domain 2, which rotates to allow the hairpins to pen-
etrate the membrane, were excluded to ensure that the mutations did not prevent pore formation itself. 
All mutants were produced and purified as for wild-type pneumolysin. As with wild-type protein they 
eluted from a gel-filtration column as single peaks, corresponding to monomers, and circular dichroism 
and fluorescence spectroscopy (Fig. 4B) confirmed that they were folded.
Almost all the mutations reduced the ability of pneumolysin to lyse sheep red blood cells, but by 
different degrees (Figs 4A and 5A and Table 2). The most striking effects were observed for the single 
mutations Asn339Arg and Asp205Arg, which failed to lyse sheep erythrocytes at the highest concentra-
tions tested (10 μ M) reflecting > 3000-fold-fold decrease of hemolytic activity (Table  2). Both residues 
are located towards in the middle of the binding interface within domain 1 (Fig. 5A). Other mutations 
in domain 1 also lead to large decreases in activity, including Thr88Glu, Arg147E and Arg226Ala and 
to a lesser extent Ser68Glu and Asn86Arg. The mutation Thr304Arg within domain 3, also resulted 
Figure 2. Packing of monomers in the pneumolysin crystal reveals the packing of the pre-pore 
complex. (A) Crystal structures of pneumolysin (PLY), intermedilysin (ILY) and perfringolysin (PFO) 
reveal differences in the angle between domains 1–3 and domain 4. (B) overlay of two fitted models into 
the prepore cryoEM density (grey surface; PDB: 2BK27) with adjacent monomers from the crystal structure 
(cyan and green). The rms deviation was 4.90 Å (over 849 Cα atoms).
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Figure 3. The conserved interface between adjacent pneumolysin monomers. (A) The convex and (B) 
concave interacting surfaces showing the electrostatic potential. Regions buried by the interaction are shaded 
in yellow and purple and key residues are labelled. (Lower panel) Alignment of the sequence of pneumolysin 
with other CDCs. Residues forming the interfaces in crystal structures of pneumolysin (PLY), intermedilysin 
(ILY) and lysteriolysin (LLO) are shaded as in part (A and B) above. Residues that are conserved in 
perfringolysin O (PFO), anthrolysin O (ALO) and suilysin (SLO) are shaded accordingly. Similar residues 
are in green.
www.nature.com/scientificreports/
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in a large decrease in activity (300-fold). In the structure, the threonine side chain forms part of a β 
strand that packs against the hydrocarbon portion of the side chain of Lys268. This strand may displaced 
upon oligomerisation on the membrane to allow the monomers to pack together to form the ring. Only 
three mutations had relatively little effect on haemolysis (≤ 2-fold): Leu11Arg, Asp338Ala and V341Arg. 
Interestingly, all three residues are located in the posterior region of domain 1, which forms the outer 
part of the pre-pore ring, towards the perimeter of the binding interface. The clustering of these residues 
suggests that this region of the toxin may be less important for oligomerization, perhaps reflect some 
flexibility.
Mutations within domain 4 also reduced the haemolytic activity of pneumolysin. Replacement of 
Tyr461 with an alanine residue lead to a five-fold decrease in activity, whereas the Tyr461Phe mutation 
Figure 4. Hemolytic activities and biophysical properties of mutant pneumolysins. (A) hemolysis of 
sheep erythrocytes by selected pneumolysin mutants. (B) Fluorescence spectra of folded and unfolded 
pneumolysin (in 2M guanidine-HCl) and pneumolysin with liposomes. The fluorescence spectra of all 
mutants were comparable to that of the wild-type and exhibited similar changes with respect to the 
fluorescence intensity and λ em, max. (C,D), denaturation of wild-type and mutant pneumolysins measured 
by changes in fluorescence intensity (C) and λ em, max (D). The unfolding transition measured by the change 
in λ em, max corresponded approximately to the decrease in fluorescence observed in (C). (E) cholesterol-
mediated inhibition of haemolysis by wild-type and mutant pneumolysins. Data are average of six 
measurements.
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Figure 5. Contributions of residues towards haemolytic activity revealed by site directed mutagenesis. 
(A) Convex (L) and concave faces (R) of pneumolysin showing the positions of the mutations and the 
relative changes in hemolytic activity. (B) Packing between adjacent membrane-binding domains in the 
putative membrane binding conformation of pneumolysin (full-length pneumolysin structure). Glu434 
forms a salt-bridge with Arg399 of the adjacent molecule and also orientates Arg437 to forms part of the 
monomer-monomer interface. (C) Substitution with the domain 4 structure (orange) reveals that the polar 
network is lost when the tryptophan-rich loop is fully or partially retracted as is predicted to occur in 
solution. In this way, membrane binding would promote oligomerization of pneumolysin monomers on the 
cell surface.
Protein EC50 (nM)
Relative Hemolytic 
Activity
Wild type PLY 2.6 ± 0.5 1.0
Leu11Arg 4.6 ± 1.6 0.69 ± 0.35
Ser68Glu 16.2 ± 1.6 0.16 ± 0.03
Asn86Arg 14.7 ± 1.5 0.18 ± 0.03
Thr88Glu 76 ± 20 0.039 ± 0.017
Arg147Ala 11 ± 1 0.24 ± 0.03
Arg147Glu 115 ± 2 0.023 ± 0.002
Asp205Arg > 10000 < 0.0003
Arg226Ala 48 ± 16 0.064 ± 0.031
Thr304Arg 900 ± 200 0.0031 ± 0.0013
Asp338Ala 2.9 ± 1.1 1.1 ± 0.3
Asp338Arg 1.4 ± 0.4 0.53 ± 0.11
Asn339Arg > 10000 < 0.0003
Val341Arg 2.5 ± 1.0 1.3 ± 0.8
Arg399Ala 15 ± 0.91 0.17 ± 0.02
Glu434Ala 22 ± 1 0.12 ± 0.02
Arg437Ala 21 ± 1 0.13 ± 0.01
Tyr461Ala 20 ± 1 0.13 ± 0.02
Tyr461Phe 1.3 ± 0.1 2.0 ± 0.3
Arg339Ala + Glu434Ala 48 ± 1 0.051 ± 0.003
Glu434Ala + Tyr461Ala 86 ± 1 0.030 ± 0.003
Glu434A + Arg437Ala 84 ± 4 0.030 ± 0.004
Table 2.  Hemolytic activities of pneumolysin mutants. Values are mean ± error from two experiments.
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had little effect, suggesting that exclusion of water at the monomer interface is more important than 
the hydrogen bonds to His407. Disruption of the small polar network involving Glu434 and Arg437 of 
one monomer and Gln402 and R399 of the adjacent monomer (by mutations Arg437Ala, Glu434Ala 
or Arg399Ala) reduced the hemolytic activity by 6 to 10-fold. In the crystal structure, Glu434 not only 
forms a salt bridge with Arg399 but also interacts with Arg437 that in turn forms part of the binding 
interface by packing against the adjacent monomer. Interestingly, these interactions are only possible 
when the tryptophan-rich loop is flipped outwards in the putative membrane-binding conformation. 
When the loop is folded back, as in the domain 4 structure or in the structure of perfringolysin O 
(Fig. 1B), Glu434 no longer contacts Arg399 or Arg437 (Fig. 5B). This mechanism would help to stabilise 
oligomerization on the membrane surface but not in solution. As expected, the Glu434Ala + Arg437Ala 
double mutant is even more disrupted than the single mutations (30-fold loss in activity). The other 
double mutations are similarly affected with 20- to 30-fold decreases in activity (Table 1).
To confirm that the mutations did not impair hemolytic activity through destabilisation or changes to 
membrane binding, we compared the stabilities and membrane binding properties of five of the mutants 
with the largest decreases in hemolytic activity: Asn339Arg, Asp205Arg, Glu434Ala, Arg147Glu and 
the double mutant Glu434Ala + Tyr461Ala. Stabilities were examined by guanidine-HCl denaturation 
and measured by fluorescence. Pneumolysin has a complex denaturation profile, probably reflecting 
its multidomain structure in which the fluorescence intensity increased over the range 0.75–1.25 M 
guanidine-HCl and then decreased from 1.25–1.75 M. Further increases in the concentration of dena-
turant resulted in no further changes, suggesting that pneumolysin was already fully unfolded (Fig. 4C). 
The decrease in fluorescence intensity was accompanied by a shift in the λ em, max from 347 nm to 354 nm, 
consistent with buried tryptophan residues becoming exposed to the polar solvent. Plotting the λ em, max 
against the concentration of guanidine-HCl gave a simple two-state transition in which the midpoint was 
~1.4 M guanidine-HCl (Fig.  4D). The five mutants all had comparable denaturation curves both with 
respect to fluorescence intensity (Fig. 4C) and λ em, max (Fig. 4D), indicating that they are not destabilised 
by the mutations.
To investigate membrane binding, we added pneumolysin to cholesterol-containing liposomes using 
fluorescence to detect any changes that occur. Liposome binding by the wild-type toxin lead to a small 
increase (~15%) in the fluorescence intensity that was accompanied by an decrease in the λ em, max from 
347 to 342 nm (Fig. 4B), presumably reflecting the tryptophan-rich loop becoming buried into the hydro-
phobic lipid bilayer. All the mutants with reduced hemolytic activities were tested in this way and showed 
comparable fluorescence changes as the wild-type toxin, both with respect to fluorescence intensity and 
λ em, max. Although, it was not possible to measure the binding affinities in this assay, these data indicate 
that the mutant toxins bind to cholesterol-containing lipid bilayers in a similar way to the wild-type 
toxin. To further examine lipid binding, a hemolytic inhibition assay was used for the 3 mutants that 
showed some residual haemolytic activity. In this assay, pneumolysin was incubated with increasing 
concentrations of cholesterol prior to the addition of sheep erythrocytes. Cholesterol inhibited hemoly-
sis by wild-type pneumolysin with an IC50 of 20 nM. IC50 values of 9, 14 and 15 nM were measured for 
the Glu434Ala, Arg147Glu and Glu434Ala + Tyr461Ala mutants, respectively, indicating that they bind 
cholesterol with comparable affinities to the wild-type toxin. Taken together, these data show that the 
loss in hemolytic activity is not caused by changes in stability or cholesterol binding. Thus, the mutations 
probably disrupt intermolecular packing of pneumolysin monomers on the membrane surface prior to 
pore formation.
Discussion
It has been shown that pneumolysin oligomerises spontaneously in solution but only at high protein con-
centrations, revealing weak interactions between monomers, even in the absence of a cholesterol-containing 
lipid bilayer21,22. We propose that these interactions have been captured in the crystals of pneumolysin 
and this conclusion is strengthened by the structures of intermediolysin and listeriolysin O, which pack 
together in a similar way. The structure reveals shape and charge complementarity between adjacent 
pneumolysin monomers in which a concave, more-negatively charged surface packs against a convex 
more positive face. The buried surface is modest compared to stable protein-protein complexes23, as 
would be expected for a protein that is predominantly monomeric at physiological concentrations. Upon 
binding to a lipid bilayer however, diffusion in only two possible planes would favour oligomerisation 
to form the pre-pore. Self-association is likely to be further favoured by additional interactions that only 
occur once pneumolysin monomers have bound to the membrane surface. Thus, the small polar network 
involving Glu434 and Arg437 of one monomer and Gln402 and Arg399 of its neighbour is only possi-
ble when the tryptophan-rich flips outwards in the putative membrane-binding conformation (Fig. 5B). 
In solution, Glu434 does not contact Arg437, so is unable to contribute towards monomer-monomer 
packing.
Monomers are parallel in the crystal structure but must be slightly offset on the cell membrane to 
create the ring-shaped pre-pore and pore oligomers. Furthermore, pores vary in size, typically with 
between 30–50 subunits, so there must be some tolerance in the intermolecular packing (ranging from 
an offset of 12° in a 30mer to 7.2° in a 50mer). Notably, most of the packing interactions in the crystal 
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are within the central portion of the binding interface (rather than towards the edges, which would tend 
to lock the interaction) and are therefore likely to allow some leeway in the angle between monomers.
Most of the contacts between pneumolysin monomers are between residues in domains 1 and 4, at the 
top and bottom of the toxin, respectively. These domains are believed to change conformation the least 
during pore formation, with domain 4 serving as a fixed membrane anchor throughout and domain 1 
acting as a bridge between domain 2, which rotates as the pre-pore collapses down to form the pore, and 
domain 3, which rearranges to form the β -hairpins that penetrate the membrane7. It is likely therefore 
that at least some of the intermolecular contacts involving domains 1 and 4 are retained within the pore 
state, thereby stabilising the oligomers during and after the major conformational change.
Recently it has emerged that pneumolysin and several other CDC are lectins that probably have dual 
receptors on host cells involving a carbohydrate ligand as well as cholesterol24. Pneumolysin binds to 
sialyl-Lewis X on red blood cells. Significantly, the putative carbohydrate-binding residues that were 
identified in this study are not involved in or buried by the intermolecular interactions identified in our 
work, allowing simultaneous receptor binding and pre-pore formation on the membrane surface.
Pneumolysin is a target for inhibitors for the treatment of pneumococcal disease because of its impor-
tance for pneumococcal pathogenicity and its conservation in the different S. pneumoniae serotypes. 
Disruption of pneumolysin oligomerisation is an attractive potential strategy for the future design of such 
inhibitors and the structure described here forms the basis for rational approaches.
Methods
Production and purification of wild-type and mutant pneumolysin and domain 4. The gene 
encoding pneumolysin from serotype D39 was amplified by PCR and cloned into the polylinker of a 
modified pET-based expression vector. Protein was synthesised with an N-terminal His6 tag. Freshly 
transformed E. coli BL21 (DE3) were grown to an OD600 of 0.6–0.8, induced with 0.1 mM IPTG and 
incubated at 18 °C, with shaking at 220 rpm overnight. Cells were harvested by centrifugation at 3,500 g 
for 15 minutes at 4 °C and resuspended in lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 20 mM imidazole 
and 1% v/v Tween 20 at pH 7.5) with a protease inhibitor tablet (Roche). Cells were lysed by sonication 
and cell debris was removed by centrifugation. The supernatant was then loaded onto an nickel-Sepha-
rose column (5 ml; GE healthcare), pre-equilibrated with lysis buffer. After loading, the column was 
washed with 50 ml lysis buffer without Tween 20 and pneumolysin was eluted using a linear gradient of 
imidazole between 0 and 1 M. Pneumolysin was further purified by gel filtration using a Superdex 200 
16/60 column in 20 mM Tris-HCl at pH 7.5. Domain 4 was expressed as a maltose-binding protein fusion 
and purified by affinity chromatography on a amylose-Sepharose column (1 ml; GE healthcare). Domain 
4 was released by overnight digestion with TEV protease and separated from maltose-binding protein 
by gel-filtration on a Superdex 200 16/60 column. Mutations were introduced into pneumolysin by PCR 
and proteins were expressed and purified as for the wild-type toxin.
Crystallization and data collection. Pneumolysin was crystallised using the sitting-drop vapor dif-
fusion method by mixing equal volumes of pneumolysin (10 mg/mL) and 100 mM Tris-Bicine pH 8.5, 
containing 30 mM CaCl2, 30 mM MgCl2, 20% v/v glycerol, 14% w/v PEG 4K, 6 mM phosphocholine 
chloride at 4 °C. Domain 4 was crystallised in 30% w/v PEG 2000 MME containing 100 mM potassium 
thiocyanate at 20 °C. All crystals were stored in liquid nitrogen and were maintained at 100 K during data 
collection. Diffraction data were collected at Diamond Light Source and were processed with Mosflm25. 
Phases for the full length protein were determined by molecular replacement with Phaser26 using the 
structure of perfringolysin as a search model (PDB: 1M3I). Phases for the domain 4 structure were deter-
mined using domain 4 of the pneumolysin structure as a search model. Models were optimized by using 
cycles of manual refinement with Coot27 and refinement in Refmac5, part of the CCP4 software suite28, 
and in Phenix29. Both wild-type pneumolysin and pneumolysin containing the double substitution 
Asp385Asn and Cys432Ala were crystallised, but the mutant consistently gave the best quality crystals.
Hemolytic assays. Sheep red blood cells (1% v/v; Thermo Scientific) were washed by pelleting 10 ml 
defibrinated sheep blood at 1734 g, at 4 °C and resuspending the cell pellet in chilled phosphate-buffered 
saline. Two-fold serial dilutions of pneumolysin in phosphate-buffered saline was aliquoted into a 
round-bottomed 96-well microtitre plate, and mixed with an equal volume of 1% v/v sheep blood. The 
plates were incubated for 30 minutes at room temperature, and intact red blood cells and cellular debris 
were pelleted by centrifugation at 1734 g, at 4 °C. The supernatant was transferred to corresponding wells 
in a flat-bottomed 96-well microtitre plate and the absorbance of each well was measured at 410 nm. 
Inhibition assays were carried out in a similar way except that dilutions of cholesterol were added to a 
fixed amount of pneumolysin (0.626 μ M). This concentration of pneumolysin was sufficient to lyse the 
erythrocytes even for the mutants with reduced haemolytic activity.
Fluorescence. Fluorescence data were collected in a Fluoromax-4 (Horiba Jobin Yvon) instrument 
at a final protein concentration of 1 μ M pneumolysin, using a low-volume quartz fluorescence cuvette 
(300 μ l). Proteins were excited at 280 nm with a 2.5 nm slit width and fluorescence was detected between 
300 and 400 nm at 1 nm intervals with a 2.5 nm slit width. All spectra were collected at 20 °C. Samples 
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were allowed to equilibrate for 150 seconds before spectra were collected and buffer blanks were sub-
tracted from all datasets.
Liposomes. Liposomes were generated by addition of L-α -phosphatidylcholine (130 μ moles; 100 mg) 
to cholesterol (130 μ moles; 50 mg) and dihexadecyl phosphate (13 μ moles; 7.1 mg) to 5 ml of a 1:1 meth-
anol/chloroform mix in a glass volumetric flask (5 ml). The mixture was solubilized by agitation and the 
liquid removed under a dry stream of nitrogen on ice. The nitrogen was stopped once all visible liquid 
had evaporated and the lipids were a translucent yellow gel sticking to the sides of the flask. The lipids 
were suspended in 5 ml of PBS by vortexing and then sonicating at room temperature, for 90 seconds.
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